Cargando…
In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells
Pegvisomant (PEG), an antagonist of growth hormone (GH)-receptor (GHR), normalizes insulin-like growth factor 1 (IGF1) oversecretion in most acromegalic patients unresponsive to somatostatin analogs (SSAs) and/or uncontrolled by transsphenoidal surgery. The residual GH-secreting tumor is therefore e...
Autores principales: | Cuny, Thomas, Zeiller, Caroline, Bidlingmaier, Martin, Défilles, Céline, Roche, Catherine, Blanchard, Marie-Pierre, Theodoropoulou, Marily, Graillon, Thomas, Pertuit, Morgane, Figarella-Branger, Dominique, Enjalbert, Alain, Brue, Thierry, Barlier, Anne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064756/ https://www.ncbi.nlm.nih.gov/pubmed/27267119 http://dx.doi.org/10.1530/ERC-16-0140 |
Ejemplares similares
-
Dose-Dependent Dual Role of PIT-1 (POU1F1) in Somatolactotroph Cell Proliferation and Apoptosis
por: Jullien, Nicolas, et al.
Publicado: (2015) -
Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro
por: Graillon, Thomas, et al.
Publicado: (2017) -
Somatotroph Tumors and the Epigenetic Status of the GNAS Locus
por: Romanet, Pauline, et al.
Publicado: (2021) -
The risks of overlooking the diagnosis of secreting pituitary adenomas
por: Brue, Thierry, et al.
Publicado: (2016) -
Current and Emerging Medical Therapies in Pituitary Tumors
por: Sahakian, Nicolas, et al.
Publicado: (2022)